Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antitumor immunotherapy]

J Z Błoński1, K Warzocha

  • 1II Klinika Chorób Wewnetrznych Instytutu Medycyny Wewnetrznej Akademii Medycznej w Lodzi.

Postepy Higieny I Medycyny Doswiadczalnej
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).

Leukemia·2017
Same author

FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.

Oncogene·2016
Same author

IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.

Tissue antigens·2014
Same author

Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.

Tissue antigens·2007
Same author

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

Bone marrow transplantation·2007
Same author

Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.

Chemotherapy·2005

New immunotherapies show promise in cancer treatment. While cellular therapies have limitations, monoclonal antibodies and engineered cytokines offer effective new strategies against tumors.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Context:

  • Review of current immunotherapy modalities in clinical oncology.
  • Assessment of the clinical effectiveness of various immunotherapies.
  • Discussion of limitations in current cellular adoptive therapy.

Purpose:

  • To present novel immunotherapy strategies for cancer treatment.
  • To evaluate the efficacy of monoclonal antibodies and recombinant cytokines.
  • To explore the potential of genetic engineering in developing advanced immunotherapies.

Summary:

  • Monoclonal antibodies targeting tumor-associated antigens show significant promise, especially when conjugated with cytotoxic molecules.
  • Recombinant cytokines, including interferons, IL-2, and CSFs, have expanding clinical applications.

Related Experiment Videos

  • Genetic engineering enables the creation of modified cytokines and fusion proteins for enhanced therapeutic effects.

    • Impact:

    • Immunotherapy, alongside gene therapy, is poised to become a powerful future tool in oncology.
    • Advancements in immunotherapy offer new hope for improved cancer treatment outcomes.
    • The development of novel protein structures through genetic engineering expands therapeutic possibilities in cancer care.